%0 Journal Article
%A Rocha-de-Lossada, Carlos
%A Linero, Carmen Alba
%A Ortega, Álvaro Santos
%A Calvo-de-Mora, Marina Rodríguez
%A Rachwani, Rahul
%A Borroni, Davide
%A Alba, Emilio
%A Orgaz, Manuel Benavides
%A Romano, Vito
%T Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
%D 2021
%U http://hdl.handle.net/10668/21667
%X The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
%~